Humana Inc. $HUM Shares Purchased by Tidal Investments LLC

Key Points

• Tidal Investments increased its Humana position by 24.5% in the second quarter, acquiring 92,496 additional shares for a total of 470,587 shares worth approximately $186.9 million. Institutional investors collectively own 92.38% of HUM.
• Humana reported quarterly earnings of $7.61 per share, exceeding estimates of $7.27, while revenue rose 26.2% year over year to $40.89 billion.
• The company declared a quarterly dividend of $0.885 per share, equivalent to an annualized $3.54 dividend and a 0.9% yield. Analysts have an overall “Hold” rating, with an average price target of $403.91.

Tidal Investments LLC grew its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 24.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 470,587 shares of the insurance provider's stock after acquiring an additional 92,496 shares during the quarter. Tidal Investments LLC owned about 0.39% of Humana worth $186,927,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HUM. Wilkerson Advisory Group LLC grew its holdings in shares of Humana by 24.6% during the 2nd quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider's stock worth $66,000 after purchasing an additional 33 shares during the period. Cidel Asset Management Inc. raised its holdings in Humana by 1.1% in the second quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider's stock valued at $1,542,000 after buying an additional 41 shares during the period. Bogart Wealth LLC raised its holdings in Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after buying an additional 48 shares during the period. Fiduciary Alliance LLC lifted its position in Humana by 0.9% during the first quarter. Fiduciary Alliance LLC now owns 5,628 shares of the insurance provider's stock valued at $976,000 after buying an additional 49 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in Humana by 20.0% during the second quarter. Parkside Financial Bank & Trust now owns 324 shares of the insurance provider's stock valued at $129,000 after buying an additional 54 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM stock opened at $401.06 on Thursday. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $428.88. The company has a market capitalization of $48.16 billion, a PE ratio of 37.94, a price-to-earnings-growth ratio of 2.64 and a beta of 0.74. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The firm has a fifty day simple moving average of $388.61 and a 200-day simple moving average of $301.31.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. The firm had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The firm's revenue was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.27 EPS. Equities research analysts anticipate that Humana Inc. will post 9 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 27th. Shareholders of record on Friday, October 30th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, October 30th. This represents a $3.54 annualized dividend and a yield of 0.9%. Humana's payout ratio is currently 33.49%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. TD Cowen increased their price objective on shares of Humana from $350.00 to $370.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Oppenheimer reaffirmed an "outperform" rating and set a $405.00 price target on shares of Humana in a research report on Thursday, July 30th. Weiss Ratings raised Humana from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, August 14th. Guggenheim boosted their price objective on Humana from $269.00 to $471.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Humana in a research report on Thursday, July 30th. They issued a "hold" rating for the company. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Humana currently has an average rating of "Hold" and an average target price of $403.91.

About Humana

Humana Inc NYSE: HUM is a U.S.-based health insurance and health care services company focused primarily on government-sponsored programs. Its offerings include Medicare Advantage plans, Medicare prescription drug plans, Medicaid coverage and specialty insurance products, serving individuals, employers and government organizations.

Through its CenterWell business, Humana also provides senior-focused primary care, pharmacy services and home health care. These operations are designed to support coordinated care for older adults and other members with ongoing health care needs.

Humana was founded in 1961 as a nursing-home company and later expanded into hospital ownership before shifting its focus toward health insurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.